Bob Smith serves as Porosome Therapeutics’ Chief Commercial Officer, with responsibility for global commercialization of the company’s medicines. Bob has over 25 years of biopharmaceutical experience ranging from large pharmaceutical to start-up biotechs focusing on the launch and commercialization of transformational and life-saving therapies. Most recently he served on Actelion’s U.S. Executive Leadership Team during the $30 billion acquisition by Johnson & Johnson.
Bob has a Bachelor of Business Administration in Marketing from Texas A&M University, and Executive Education from the Harvard Business School, the Wharton School and the International Institute for Management Development (IMD). He also serves on the board of the Scleroderma Research Foundation (SRF).